NVSNovartis PharmaceuticalsRunning, no new patients
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Tuberous Sclerosis Complex
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 206 (final count)
- Started
- Aug 23, 2017
- Main results expected
- Dec 30, 2026
- Fully finished
- Dec 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurances of adverse events and serious adverse events
Measured over: Day 1 up to approximately 10 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02962414 · record last updated 2026-08-21 · checked 2026-11-09 15:47 UTC